Immunotherapy of multiple sclerosis - Current practice and future directions

Journal of Rehabilitation Research and Development

Volumn 39, Issue 2, 2002, Pages 273-286

  Tullman, Mark J ^a   Lublin, Fred D ^a   Miller, Aaron E ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Disease modifying agents; Immunomodulatory; Immunosuppressive; Immunotherapy; Multiple sclerosis; Treatment

Indexed keywords

DISEASES; NEUROLOGY; PATIENT TREATMENT;

MULTIPLE SCLEROSIS (MS);

PATIENT REHABILITATION;

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION; CLINICAL TRIAL; FEMALE; FORECASTING; MALE; PROGNOSIS; REVIEW; STANDARD; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; FEMALE; FORECASTING; HUMAN; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; HUMANS;

EID: 0036017499     PISSN: 07487711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Multiple sclerosis: Treatment of acute exacerbations with corticotrophin (ACTH)
2. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo - Final report
3. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
4. Intravenous methylprednisolone for multiple sclerosis in relapse
5. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis
6. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
7. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
8. The effect of corticosteroids for acute optic neuritis on the subsequent develop-ment of multiple sclerosis
9. The optic neuritis treatment trial: Three-year follow-up results
10. Methylprednisolone therapy in multiple sclerosis: A profile of adverse effects
11. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
12. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
13. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
14. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis
15. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis
16. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebocontrolled study of interferon-beta la in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta la Subcutaneously in Multiple Sclerosis
17. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
18. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
19. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
20. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
21. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-lb: Experience during the first three years
22. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-lb
23. The independent comparison of interferon (INCOMIN) trial: A multicenter, randomized trial comparing clinical and MRI efficacy of IFN beta-la and beta-lb in multiple sclerosis
24. Placebo-controlled multicentre randomised trial of interferon β-lb in treatment of secondary progressive multiple sclerosis
25. Effect of interferon-beta lb on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
26. The North American Study of Interferon beta-lb in secondary progressive multiple sclerosis
27. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis
28. PRISMS-4: Long-term efficacy of interferon-β-la in relapsing MS
29. Results of comparative efficacy trial using two formulations of interferon beta-1a in RRMS
30. Randomized controlled trial of interferon-beta-la in secondary progressive MS: Clinical results
31. Randomized controlled trial of interferonbeta-la in secondary progressive MS: MRI results
32. Depression as a major symptom of multiple sclerosis
33. The spectrum of depression in multiple sclerosis. An approach to clinical management
34. Causes of death in patients attending multiple sclerosis clinics
35. Mechanisms of action of glatiramer acetate in multiple sclerosis
36. Primary progressive MS (PPMS): Clinical and MRI characteristics at entry into the PROMiSe trial
37. A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year
38. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
39. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
40. Mitoxantrone in progressive multiple sclerosis: A placebo controlled, randomized, observer-blind phase III trial: Clinical results and three-year follow-up
41. Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study - MRI results
42. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
43. Overview of azathioprine treatment in multiple sclerosis
44. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study
45. Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
46. Cladribine in treatment of chronic progressive multiple sclerosis
47. The treatment of chronic progressive multiple sclerosis with cladribine
48. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
49. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter, controlled trial
50. Intense immunosuppression in chronic progressive multiple sclerosis: The Kaiser study
51. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years
52. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
53. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
54. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial
55. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
56. Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs
57. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients
58. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
59. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy
60. Immunoblative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis
61. Autologous hematopoietic stem cell transplantation suppress Gd-enhanced MRI activity in MS
62. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
63. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
64. Intravenous immunoglobulin treatment in multiple sclerosis
65. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
66. ESIMS - An ongoing trial in secondary progressive multiple sclerosis
67. Rate of pregnancy-related relapse in multiple sclerosis
68. High dose IVIG in the postpartum period for prevention of exacerbations in MS
69. A trial to assess the safety of combining therapy with interferon beta-la and glatiramer acetate in patients with relapsing MS
70. Medical progress: Multiple sclerosis
71. Human tumor necrosis factoralpha augments experimental allergic encephalomyelitis in rats
72. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis
73. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins
74. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
75. TNF neutralization in MS: Results of a multicenter, randomized, placebo-controlled study
76. Effects of phosphodiesterase inhibitors on cytokine production by microglia
77. Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors
78. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS
79. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems, and perspectives